Ocular Hypertension - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Ocular Hypertension - Pipeline Review, H2 2018’, provides an overview of the Ocular Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ocular Hypertension

- The report reviews pipeline therapeutics for Ocular Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Ocular Hypertension therapeutics and enlists all their major and minor projects

- The report assesses Ocular Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Ocular Hypertension

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aerie Pharmaceuticals Inc

Allergan Plc

Angelini Group

Can-Fite BioPharma Ltd

D. Western Therapeutics Institute Inc

Ironwood Pharmaceuticals Inc

Kowa Co Ltd

Laboratorios SALVAT SA

Laboratorios ...

Aerie Pharmaceuticals Inc

Allergan Plc

Angelini Group

Can-Fite BioPharma Ltd

D. Western Therapeutics Institute Inc

Ironwood Pharmaceuticals Inc

Kowa Co Ltd

Laboratorios SALVAT SA

Laboratorios Sophia SA de CV

Lee's Pharmaceutical Holdings Ltd

Neurim Pharmaceuticals Ltd

NicOx SA

Novartis AG

Ocular Therapeutix Inc

Santen Pharmaceutical Co Ltd

Senju Pharmaceutical Co Ltd

Shire Plc

Sun Pharma Advanced Research Company Ltd

Sylentis SAU

Taejoon Pharm Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Ocular Hypertension – Overview 6

Ocular Hypertension – Therapeutics Development 7

Ocular Hypertension – Therapeutics Assessment 16

Ocular Hypertension ...

Table of Contents

Table of Contents 2

Introduction 5

Ocular Hypertension – Overview 6

Ocular Hypertension – Therapeutics Development 7

Ocular Hypertension – Therapeutics Assessment 16

Ocular Hypertension – Companies Involved in Therapeutics Development 25

Ocular Hypertension – Drug Profiles 35

Ocular Hypertension – Dormant Projects 112

Ocular Hypertension – Discontinued Products 114

Ocular Hypertension – Product Development Milestones 116

Appendix 125

List of Tables

List of Tables

Number of Products under Development for Ocular Hypertension, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Ocular Hypertension, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Ocular Hypertension – Pipeline by Aerie Pharmaceuticals Inc, H2 2018

Ocular Hypertension – Pipeline by Allergan Plc, H2 2018

Ocular Hypertension – Pipeline by Angelini Group, H2 2018

Ocular Hypertension – Pipeline by Can-Fite BioPharma Ltd, H2 2018

Ocular Hypertension – Pipeline by D. Western Therapeutics Institute Inc, H2 2018

Ocular Hypertension – Pipeline by Ironwood Pharmaceuticals Inc, H2 2018

Ocular Hypertension – Pipeline by Kowa Co Ltd, H2 2018

Ocular Hypertension – Pipeline by Laboratorios SALVAT SA, H2 2018

Ocular Hypertension – Pipeline by Laboratorios Sophia SA de CV, H2 2018

Ocular Hypertension – Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018

Ocular Hypertension – Pipeline by Neurim Pharmaceuticals Ltd, H2 2018

Ocular Hypertension – Pipeline by NicOx SA, H2 2018

Ocular Hypertension – Pipeline by Novartis AG, H2 2018

Ocular Hypertension – Pipeline by Ocular Therapeutix Inc, H2 2018

Ocular Hypertension – Pipeline by Santen Pharmaceutical Co Ltd, H2 2018

Ocular Hypertension – Pipeline by Senju Pharmaceutical Co Ltd, H2 2018

Ocular Hypertension – Pipeline by Shire Plc, H2 2018

Ocular Hypertension – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018

Ocular Hypertension – Pipeline by Sylentis SAU, H2 2018

Ocular Hypertension – Pipeline by Taejoon Pharm Co Ltd, H2 2018

Ocular Hypertension – Dormant Projects, H2 2018

Ocular Hypertension – Dormant Projects, H2 2018 (Contd..1), H2 2018

Ocular Hypertension – Discontinued Products, H2 2018

Ocular Hypertension – Discontinued Products, H2 2018 (Contd..1), H2 2018

List of Figures

List of Figures

Number of Products under Development for Ocular Hypertension, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Ocular Hypertension, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports